These clinical samples were then subjected to multiplex IHC staining to evaluate the expression levels of each inhibitory ligand (PD-L1, CEACAM-1, LSECtin, and MHC class II), cytotoxic T cell marker CD8 and tumor marker Cytokeratin (Fig. 1a). This evidence concerns the gene CEACAM1 and neoplasm.